MedTrace Logo

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

NCT05937152 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-03-06

No results posted yet for this study

Summary

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

Conditions

  • Diabetic Polyneuropathy

Interventions

DRUG

Eptinezumab

Intravenous (IV) infusion of 300 mg

DRUG

Placebo

Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)

Sponsors & Collaborators

Principal Investigators

  • Narayan Kissoon, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States
  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05937152 on ClinicalTrials.gov